Grand Pharmaceutical Group Ltd
Grand Pharmaceutical Group Ltd is a pharmaceutical company that develops, produces, and markets a range of pharmaceutical products, primarily in the healthcare sector.
Business. Grand Pharmaceutical Group Ltd (0512.HK) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Grand Pharmaceutical Group Ltd (0512.HK) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Grand Pharmaceutical Group Ltd maintains a relatively strong liquidity position, with a current ratio of 1.14, indicating that its current assets slightly exceed its current liabilities. However, the company's free cash flow is negative at -606.38 million HKD, and capital expenditures are significant at -1.52 billion HKD, suggesting ongoing investment in operations. The company's debt-to-equity ratio is 0.28, which is relatively low, indicating a conservative capital structure.
In terms of profitability, the company's return on equity (ROE) is 7.29%, and its return on assets (ROA) is 4.57%, both of which are positive but should be compared to industry medians to assess relative performance. The company's net income of 1.24 billion HKD and operating income of 1.58 billion HKD reflect a healthy level of profitability. Gross profit of 6.78 billion HKD suggests strong cost control in production.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of geographic segmentation may indicate a high concentration of revenue in a specific region, which could pose a concentration risk if not disclosed in the input data.
Looking ahead, the company's revenue is expected to grow, though the exact growth rate is not provided in the input data. Analysts have provided a mean price target of 11.85 HKD, with a median of 11.85 HKD, and a high of 12.00 HKD, indicating a generally positive outlook. The mean recommendation is 1.50, which is a strong buy signal, with two strong-buy and two buy ratings.
The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its cash flow carefully to avoid liquidity constraints. The dilution risk is low, and there is no indication of near-term dilution pressure in the input data.
Recent events, including analyst estimates and price targets, suggest a positive sentiment among investors. The company has not disclosed any recent filings or transcripts that would indicate significant changes in its business operations or strategic direction.
- The company has a conservative capital structure with a low debt-to-equity ratio of 0.28.
- Free cash flow is negative, indicating ongoing investment in operations.
- Analysts have a generally positive outlook, with a mean price target of 11.85 HKD.
- The company's profitability is reflected in a ROE of 7.29% and ROA of 4.57%.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,52 |
| Revenue | —no estimate | —no estimate | 13,3B HKD |
| Operating income | —no estimate | —no estimate | 1,3B HKD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Grand Pharmaceutical Group Ltd Market data — financials · 2026-05-26
- Grand Pharmaceutical Group Ltd Market data — analyst estimates · 2026-05-26